Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1998American Medical Association
The FDA is alerting physicians and other health professionals to concerns about subcutaneous administration of terbutaline sulfate via infusion pump for off-label use as treatment and prevention of preterm labor (tocolytic therapy). Terbutaline sulfate is approved only for the treatment of asthma, and the approved labeling for terbutaline sulfate injection states that the drug should not be used for the management of preterm labor. The only drug currently approved for tocolytic therapy is ritodrine hydrochloride injection.
Nightingale SL. Warning on Use of Terbutaline Sulfate for Preterm Labor. JAMA. 1998;279(1):9. doi:10.1001/jama.279.1.9-JFD71011-2-1
Customize your JAMA Network experience by selecting one or more topics from the list below.